Abstract:Background: Rare or orphan diseases have become an important target of healthcare activities all over the world. The study aims to identify ethical questions linked to rare diseases and orphan drugs and ethical principles or approaches applied to solve them. Methods: Relevant peer-reviewed articles were identified by means of a systematic review. The literature was searched from 20 May 2020 to 20 June 2020. The search included the databases PubMed, Scopus and Web of Science (2010 - April 2020). A total of 4,139 papers related to rare diseases were identified; with 1,205 papers obtained from Scopus; 2,476 papers from PubMed; and 458 from Web of Science with keyword search "ethics" AND "rare" AND "disease", "ethical" AND "orphan", "ethical" AND "orphan" AND "drug", and "ethical" AND "rare" AND "disease". Finally, XX studies were chosen for further analysis. Results: The main findings reveal five main ethical issues. The most essential one shows that funding research and development in the field of orphan drugs poses an almost impossible dilemma. Other issues include the significance of non-economic values like compassion and beneficence in decision-making related to orphan drugs and rare diseases; the identification of limits to labelling diseases as rare; barriers to global, supranational and international cooperation; and last but not least, determining and establishing panels of decision-makers. Conclusions: A strictly global approach would be the most appropriate way to deal with rare diseases. Nonetheless, international, let alone global, cooperation seems to be completely beyond the reach of the current international community, although the EU, for instance, has a centralized procedure for labelling orphan drugs. This deficit in international cooperation can be partly explained by the fact that the current technologically globalized world still lacks globally accepted ethical values and rules. This is further aggravated by unresolved international and intercultural conflicts. In addition, the sub-interests of various parties as well as the lack of desire to deal with other people's problems need to be taken into account. The aforementioned problems are difficult to avoid. Nevertheless, let us be cautiously optimistic. At least, there are people who raise ethical questions about rare diseases and orphan drugs.

Commentary: Which Principles Should Apply for a National Strategy on Rare Diseases?

Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?

The next generation of rare disease drug policy: ensuring both innovation and affordability

Pharmaceutical policy and innovation for rare diseases: A narrative review

Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review

Unlocking the full potential of rare disease drug development: exploring the not-for-profit sector's contributions to drug development and access

Review of 11 national policies for rare diseases in the context of key patient needs

Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective

Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)

Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations

[Authorization and reimbursement of orphan drugs in an international comparison]

Data silos are undermining drug development and failing rare disease patients

Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases

Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review

Prioritization of research engaged with rare disease stakeholders: a systematic review and thematic analysis

Reliably Assessing "Value" While Addressing High Prices

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group

The Role of Pharmacogenomics in Rare Diseases

Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications